Bullish Case: Known: SLDB $9.72, flat recently, SPY IV moderate. SLDB IV surface has a lower-vol pocket near ATM (~9–11) but very high far-tail IV. Inferred from the SLDB return surface: history clusters around small negatives (~-5%) more than durable gains. Compared with your prior bullish (placement + INSPIRE), the rerating hasn’t shown up; Helium’s prior +1.67% call had weak correlation (-0.1). Falsifiable: clinical/partner update without fresh heavy dilution.

Bearish Case: Known: put volume dwarfs call volume (762%), including heavy 07/17/26 9P trading; SLDB IV surface shows extreme far-OTM put IV and backwardation. Inferred from the SLDB return surface: likelihood concentrates near small negative outcomes (~-5%), not sustained mean reversion. Your prior bearish “fear/gap risk” hasn’t yet produced a large drawdown (only -12.8% weekly), so downside may be deferred. Uncertain: cash/financing vs genuine efficacy. Falsifiable: SEC raise/going-concern or trial setback.

Potential Outcomes:

1. 45% Rangebound (-4% to +6%): IV trough near $9–11 and return-surface mass around ~-5%; no major catalyst before 7/17–9/18.
2. 30% -20%–-40%: dilution/endpoint miss signaled by SEC raise or negative trial update; put-skew + backwardation.
3. 15% +20%–+60%: enrollment/safety/partner traction improves without heavy financing.
4. 7% +100%+: FDA/regulatory or pivotal INSPIRE success notice.
5. 3% ~0: going-concern/bankruptcy filing.

July 14, 2026